[Solved] Psilocybin in Idiopathic Pulmonary Fibrosis (IPF)

Psilocybin could potentially play a supportive role in idiopathic pulmonary fibrosis (IPF), particularly in light of recent research into the effects of psilocybin at the cellular level and the protection of telomeres. IPF is a serious lung condition in which scar tissue (fibrosis) builds up in the lungs, leading to progressive breathing difficulties. One of the underlying problems in IPF is the accelerated shortening of telomeres in lung cells, which leads to cellular ageing and a loss of regenerative capacity.

The article Psilocybin against DNA aging and telomere protection shows that psilocin (the active compound in psilocybin) can, in laboratory studies, extend the lifespan of cells by up to 57%, partly by maintaining telomere length. Improved vitality and a longer lifespan were also observed in mice. These effects are linked to increased activity of the enzyme SIRT1, which repairs DNA and protects telomeres. This offers promising leads for conditions such as IPF, where telomere damage plays a crucial role.

Although there is as yet no clinical evidence to support the effectiveness of psilocybin specifically for IPF, this disease is included on the list of conditions for which psilocybin might be beneficial, based on this biochemical mechanism.

Additional recommendation: A further consideration is the combining psilocybin with a selective 5-HT₂B antagonist. This could potentially suppress the adverse effects of 5-HT₂B receptor activation caused by psilocybin or psilocin, whilst preserving the desired effects mediated via 5-HT₂A. By adding a 5-HT₂B antagonist, these undesirable effects could potentially be suppressed, whilst the desired effects via 5-HT₂A – such as expanded consciousness, immune modulation and anti-inflammatory effects – are retained. This approach could widen the therapeutic window of psilocybin, particularly for conditions such as IPF where the risk of fibrosis is clinically relevant. Such combination therapies are still at the experimental stage and require further pharmacological optimisation, toxicological studies and clinical evaluation, but they do represent a promising strategic route towards the safer use of psychedelics in fibrotic conditions.

For anyone considering a psilocybin session When setting this sort of physical health goal, it is important to first to complete intake. On this basis, safety risks can be assessed and targeted recommendations made, such as combining psilocybin with supplements like fisetin to support cellular rejuvenation.

Although a cure for IPF using psilocybin has not (yet) been proven, the use of psilocybin as part of a broader health plan, with professional support, may help to protect cells, reduce stress and improve overall quality of life.

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease characterised by increasing scarring (fibrosis) in the lungs. Current treatments (such as pirfenidone and nintedanib) slow the progression of the disease to some extent, but do not cure IPF. Given the limited options available, there is interest in innovative approaches. Psilocybin, a psychedelic substance found in mushrooms, and its active metabolite psilocin are known for their effects on the central nervous system (via serotonin receptors) and are being investigated for mental disorders. However, recent research suggests that these substances may also influence cellular ageing, inflammatory processes and, possibly, fibrosis. In this review, we report on the clinical and pre-clinical evidence for a therapeutic effect of psilocybin/psilocin in IPF, and we discuss relevant biochemical mechanisms – in particular, the role of sirtuin-signalling pathways (SIRT1, SIRT3, etc.), neuro- and systemic inflammation, and the influence of serotonergic signalling on fibrosis. Finally, we highlight the future potential and the challenges posed by this approach.

Clinical evidence and observations

Current clinical data: There are no clinical studies to date that have evaluated psilocybin as a treatment for IPF. In the literature, we found no reported cases of IPF patients who had been treated with psilocybin to influence the pulmonary fibrosis itself. The therapeutic application The use of psilocybin is currently limited to psychiatric conditions (depression, anxiety in terminally ill patients, etc.) and a few neurodegenerative disorders. This means that any potential benefits for IPF remain theoretical for the time being and are based primarily on indirect evidence or pre-clinical findings.

Symptom management and quality of life: Although psilocybin has not been studied for the direct treatment of fibrosis in IPF, there is interest in its use for palliative care. IPF patients often experience severe dyspnoea, anxiety and depression as a result of their diagnosis and prognosis. In other studies, psychedelic therapy (a single supervised dose) has been linked to a reduction in existential anxiety and depression in patients with terminal illnesses, with sustainable improvements in well-being. This suggests that psilocybin therapy may, in future, contribute to mental wellbeing of IPF patients in the final stages of life. However, this concerns relief of symptoms and psychosocial support, rather than treating pulmonary fibrosis itself.

Safety considerations: We know from clinical studies in other populations that psilocybin, when taken under medical supervision, generally is well tolerated, without causing serious organ damage in the short term. Nevertheless, there are significant concerns for IPF patients (who are often elderly and vulnerable). Psilocybin activates serotonin receptors throughout the body, including the heart and lungs. Chronic stimulation of certain serotonin receptors (particularly 5-HT₂B) is known to fibrotic side effects may have. For example, ~1% of patients who had been taking the migraine drug methysergide (a serotonin agonist) for many years developed severe heart valve disease and pulmonary fibrosis. This means that frequent or prolonged use of psilocybin or psilocin theoretical Fibrosis could be exacerbated via 5-HT₂B activation (see further under Serotonergic action). In a clinical context, therefore, great care should be taken with regard to dosage and frequency (possibly no (chronic microdosing), and assess the risk-benefit profile, particularly in patients with already impaired lung function.

Clinical conclusion: To summarise, there is no direct clinical evidence yet that psilocybin or psilocin can treat IPF. Any potential applications remain experimental. However, experience from other fields (e.g. oncology and psychiatry) does offer some indications of possible benefits in quality of life and anti-inflammatory effects. To have an effect on the disease progression However, targeted clinical trials are needed to prove the diagnosis of IPF.

Preclinical evidence (in vitro and in vivo)

Despite the lack of clinical data, there are preclinical findings which are relevant to IPF and psilocybin/psilocin. This evidence comes from both cell studies in vitro as animal models in vivo, and suggests that psilocin influences processes that play a role in IPF (cell ageing, fibrosis and inflammation).

1. Prolonging cellular lifespan and anti-fibrotic signalling: A recent in vitro A study investigated the effect of psilocin on human lung cells (fibroblasts). Interestingly, psilocin prolonged life expectancy of these cells was significantly affected: at a concentration of 10 μM, the number of population doublings increased, and at 100 μM, the replicative lifespan was reduced by 57% extended. Psilocin delayed the onset of cell ageing (senescence), as demonstrated by lower levels of senescence markers (p16^INK4a^, p21) and fewer β-galactosidase activity compared with untreated control cells. Importantly, psilocin treatment led to maintenance of telomere length in these ageing lung fibroblasts, whilst untreated cells exhibited shortened telomeres. Given that accelerated telomere shortening and cellular ageing contribute to the pathogenesis of IPF, these findings point to a potential anti-fibrotic effect: psilocin keeps lung cells functionally young for longer. Furthermore, a clear biochemical shift given that: psilocin increased the level of sirtuin-1 (SIRT1) in the fibroblasts and reduced oxidative stress. This indicates the activation of endogenous anti-ageing approaches (see further under Sirtuin pathways). Furthermore, the production of NADPH oxidase 4 (NOX4, a pro-oxidant protein known to drive fibrosis) decreased, whilst the level of Nrf2 (an antioxidant transcription factor) increased. In summary, these cellular experiments demonstrate that psilocin cell-protective and potentially anti-fibrotic molecular effects has, including a reduction in DNA damage and oxidative stress.

2. Effects on an in vivo ageing model: In parallel with the cell studies, a long-term animal study was carried out. Older mice (19 months old, ~60 human years) were given psilocybin over a period of 10 months (one dose per month, ranging from 5 mg/kg to 15 mg/kg). The results were remarkable: the psilocybin-treated mice lived, on average, 30% longer than untreated controls. In addition, the treated animals exhibited healthier characteristics in later life (better coat quality, less hair loss). Although this model was not a specific fibrosis model, IPF is strongly age-related; ageing processes, such as DNA damage, telomere shortening and stem cell depletion, play a role in IPF. The mouse results imply that Systemic administration of psilocybin slows age-related decline. The researchers concluded that psilocybin has multiple hallmarks of ageing had a beneficial effect: it reduced oxidative damage, improved DNA repair and preserved telomeres. This geroprotective the effects would also, indirectly, lung tissue may protect against age-related fibrosis. Interestingly, most cells in the body (including lung cells) have serotonin receptors, suggesting that psilocybin may exert direct effects on organ cells outside the brain. This is a new area of research, but these mouse data represent the first in vivo evidence that psilocybin/psilocin has a broad cellular healthy ageing may help to promote.

3. Immunomodulation and anti-inflammatory effects: Out in vitro Experiments with immune cells suggest that psilocin can modulate the behaviour of inflammatory cells. In cultured microglia (immune cells of the brain), psilocin suppressed pro-inflammatory functions: it significantly reduced the release of reactive oxygen/nitrogen species (ROS and NO) and decreased the phagocytic activity of activated microglia. Notably, these effects were mimicked by specific 5-HT₂ receptor agonists and reversed by serotonin receptor antagonists. This confirms that the 5-HT₂ subtype receptors (including 5-HT₂A and 5-HT₂C, which are present on microglia) are involved in the anti-inflammatory effects of psilocin. Although microglia form part of the central nervous system (neuroinflammation), this principle is important: many mechanisms of chronic inflammation overlap with those of peripheral inflammation. Psilocybin-like substances have also, in animal studies, peripheral anti-inflammatory effects have been demonstrated. For example, in a chronic asthma model in mice that (R)-DOI, an experimental 5-HT₂A agonist related to psychedelics, exhibited potent anti-inflammatory effects in the lungs: the eosinophilic inflammatory infiltration decreased, and airway fibrosis and collagen deposition decreased by ~70% compared with untreated sick mice. Furthermore, lung function improved (reduced airway hyper-reactivity) and mucus production decreased. These in vivo results show that activation of 5-HT₂A receptors in the lung An anti-fibrotic effect may play a role in the context of chronic pneumonia and lung remodelling. The authors of this study even regarded (R)-DOI as a new anti-fibrotic compound affecting the lungs. Although asthma and IPF are different conditions, they share some end-stage mechanisms, such as structural tissue changes caused by chronic inflammation. The fact that a psychedelic substance causes pulmonary fibrosis and inflammation counteracts in a mouse model, supports the hypothesis that psilocybin analogues have immunomodulatory anti-fibrotic effects could have.

In short (preclinical): psilocybin/psilocin shows promising results at the cellular and animal levels, which relevant to IPF are: it promotes cell survival and youthful phenotypes (via SIRT1, telomere maintenance), it reduces oxidative stress and inflammatory activation, and it may even reduce the formation of fibrotic tissue in the lungs under pathological conditions. These findings form the basis to look further into how psilocybin causes these effects – below we discuss the main mechanistic pathways.

Biochemical mechanisms of psilocybin/psilocin

Here, we focus on three interrelated mechanistic domains in which the effects of psilocybin may be relevant to IPF: (1) Sirtuin signalling pathways (SIRT1, SIRT3, etc.) which are involved in ageing and fibrosis; (2) Neuroinflammation and systemic inflammation, that is to say, the immunomodulatory properties of psilocybin; and (3) Serotonergic receptors and fibrosis, i.e. the effect of psilocybin on 5-HT receptors, which may influence fibrotic processes. These mechanisms overlap to some extent and, taken together, provide insight into how Psilocybin/psilocin could help to inhibit IPF pathology – or highlight where the risks lie.

Modulation of sirtuin pathways (SIRT1, SIRT3, …)

Sirtuins in IPF: Sirtuins (SIRT1 to SIRT7) are NAD⁺-dependent enzymes that regulate gene expression, metabolism, DNA repair and ageing. In fibrosis, they appear to endogenous inhibitors of tissue damage. Various sirtuins (SIRT1, SIRT2, SIRT3, SIRT6, SIRT7) can significantly influence the development of pulmonary fibrosis to slow down according to previous studies. IPF is associated with dysregulation of sirtuins: in the lung tissue of IPF patients, the expression of all sirtuins is lower than normal, with SIRT7 in particular showing a marked reduction. SIRT1 (the most widely studied) is crucial for repairing DNA damage and combating cellular ageing. A SIRT1 deficiency In lung fibroblasts, this leads to increased oxidative stress, persistent activation of myofibroblasts and excessive extracellular matrix deposition. Clinical measurements confirm that IPF patients have significantly lower SIRT1 levels in their serum compared with healthy controls, and that higher SIRT1 levels are associated with better lung function (FEV₁, FVC, diffusion capacity) and milder disease. SIRT1 therefore appears to protective – its loss is associated with more severe IPF. SIRT3, a mitochondrial sirtuin, exhibits a more complex pattern in IPF: although a clinical study found elevated serum SIRT3 levels in IPF patients, there is also evidence that functional SIRT3 deficiency contributes to fibrosis. SIRT3 deficiency is more common in IPF patient tissues, and SIRT3 knockout mice develop more severe pulmonary fibrosis when exposed to harmful stimuli. This is explained by the fact that SIRT3 normally mitigates mitochondrial oxidative stress (through the deacetylation of SOD2, amongst others) and suppresses inflammatory responses. In short, Adequate activity of SIRT1 and SIRT3 provides protection against the cascade of cell damage, inflammation and fibroblast activation that leads to IPF.

Effect of psilocybin/piloscin on sirtuins: Preclinical evidence suggests that psilocin has precisely this sirtuin pathways has a beneficial effect on. In fibroblast cells, psilocin led to a significant increase in SIRT1 expression. This was accompanied by measurable effects consistent with increased SIRT1 activity: reduced DNA damage (lower GADD45a levels) and reduced oxidative stress (a decrease in NOX4 and an increase in the antioxidant response). This is because SIRT1 can inhibit the production of mitochondrial ROS and attenuate fibroblast activation. The observed reduction in NOX4 The role of psilocin is relevant, as NOX4 is overactive in IPF lungs and contributes directly to fibrogenesis via ROS production and the activation of fibroblasts. Psilocin’s effect on SIRT3 has been demonstrated less directly in the literature, but we can speculate: through the general reduction in oxidative stress and improvement in mitochondrial function (telomere maintenance, reduced senescence), psilocin might also create the conditions under which SIRT3 is more active. SIRT3’s role in IPF is partly to prevent mitochondrial damage and inflammation. An analogy from another model: in ageing mice, chronic psilocybin administration ensured that NAD⁺-dependent processes (which rely on sirtuins) remained intact for longer. Although direct evidence for SIRT3 upregulation by psilocybin is lacking, this is a an interesting hypothesis for further research.

It is crucial that the anti-fibrotic effects The effects of sirtuins (reduced myofibroblast formation, inhibition of TGF-β signalling, etc.) have been demonstrated in numerous studies. Psilocybin’s ability to increase SIRT1 and cells staying healthy for longer to keep, suggests that it is a upstream modulator may trigger those fibrosis-inhibiting pathways in the lung. In summary, psilocybin would, via sirtuin activation, cell ageing and fibrosis inhibition: this has been experimentally demonstrated for SIRT1 and is theoretically plausible for SIRT3 and related pathways (given their functional overlap).

Effects on neuroinflammation and systemic inflammation

Neuroinflammation: Chronic inflammatory activity in the central nervous system (“neuroinflammation”) plays a role in neurodegenerative diseases and also in the increased systemic an inflammatory state often seen in chronic diseases. Psilocybin is known for its psychological effects, but has also recently demonstrated direct anti-inflammatory to have effects in the brain. As described above, psilocin inhibits excessive activation of microglia: it reduces the production of inflammatory mediators (ROS, NO) by these brain immune cells and curbs their phagocytic hyperactivity. Interestingly, in that study, psilocin influenced not the release of TNF-α (a cytokine) by microglia, but not their other harmful activities. This may indicate a specific mechanism of action via serotonin 5-HT₂A/2C receptors on microglia, thereby, for example, inhibiting oxidative damage without disrupting the entire cytokine cascade.

Systemic inflammation and immune modulation: The immune system outside the brain also contains many serotonin receptors, including the 5-HT₂A receptor on various white blood cells. Serotonin levels themselves are often elevated during inflammatory responses and can exacerbate inflammation via certain receptors. In particular, 5-HT₂A receptors mediate the pro-inflammatory effects of endogenous serotonin. Paradoxically, agonists of this receptor (such as psychedelics) in low doses actually potent anti-inflammatory effect demonstrate. Groundbreaking research by Nichols et al. shows that psychedelic 5-HT₂A agonists (e.g. (R)-DOI, LSD) exhibit strong effects in various models immunomodulatory effects help to reduce that inflammation without requiring hallucinogenic doses. In an acute inflammation model in mice, (R)-DOI completely reduced TNF-α-induced inflammation in several organs, even at doses well below the threshold for behavioural changes. This illustrates that the anti-inflammatory effect of psychedelics may be separate from their psychoactive effects – an important factor for potential medicinal applications.

Specific findings in peripheral tissues: In a mouse model of metabolic syndrome, (R)-DOI inhibited various pro-inflammatory biomarkers without causing generalised immunosuppression. In an 18-week chronic asthma model (in the presence of continuous allergic stimuli) (R)-DOI was able to, even after inducing disease, reversing the inflammatory damage: lung tissue from treated mice showed significantly less infiltrate and almost 70% less fibrosis structural change than untreated asthmatic mice. These anti-inflammatory and anti-remodelling effects were accompanied by a reduction in inflammatory markers (such as IL-13, IL-17 and eotaxin in bronchoalveolar lavage) and an improvement in lung function. This suggests that 5-HT₂A-mediated signalling can inhibit inflammatory pathways that also drive fibrosis. Important for IPF: although IPF is not a classic inflammatory disease (anti-inflammatory drugs such as prednisone are ineffective as a treatment), it plays inflammation does play a role in the initiation and progression – particularly via damage to alveolar epithelial cells and macrophage activation, which stimulate fibroblasts. Psilocybin’s ability to modulate inflammatory responses in both the brain and peripheral organs could therefore contribute to a less profibrotic environment in the lung.

Neuro-immune connection: In addition, there is an indirect mechanism: chronic stress, anxiety and depression (which are common in IPF) are associated with elevated systemic inflammatory markers (such as IL-6 and CRP). Successful treatment of depression often correlates with a reduction in these inflammatory markers. Psilocybin is a powerful antidepressant under development, with generally rapid and long-lasting reduction in depressive and anxiety symptoms after one or two doses. As a result, psilocybin could be used in IPF patients indirect An anti-inflammatory effect may have through an improvement in psychological well-being. The so-called “psilocybin-telomere hypothesis” posits that treating negative psychological states with psilocybin can lead to measurable biological rejuvenation (e.g. longer telomeres). After all, positive mental health states are associated with slower biological ageing, whilst chronic stress has the opposite effect. Applied to IPF, this would mean that if psilocybin reduces the mental burden and, consequently, the stress-related inflammatory signals, this would theoretical may slow the progression of fibrosis (although this has not yet been proven).

In summary: Psilocybin and psilocin have demonstrable anti-inflammatory and immunomodulatory effects, both in the CNS (microglia) and peripherally (airway inflammation, systemic inflammation). These effects occur partly via 5-HT₂A receptors and may occur at sub-hallucinogenic doses. For IPF – a disease characterised by low-grade persistent inflammation and immune-mediated fibrosis – Is this relevant: psilocybin may steer the immune system towards an anti-fibrotic response, for example by reducing the release of mediators that promote fibrosis (TNF, TGF-β activation, etc.) and by reducing oxidative damage in lung tissue. This mechanism is largely backed by experimental evidence in animal models and warrants further investigation in experiments specifically focused on IPF.

Serotonergic effects and fibrotic processes

Psilocybin and psilocin derive their effects from activation of serotonin (5-HT) receptors, particularly those of the 5-HT₂ subfamily (such as 5-HT₂A, 5-HT₂B and 5-HT₂C) and, to a lesser extent, 5-HT₁A. These receptors are expressed not only in the brain but also in the lungs (on smooth muscle cells, endothelial cells, macrophages and fibroblasts). The serotonergic system is closely intertwined with fibrosis processes; serotonin acts as a growth factor-like stimulus for connective tissue cells. It is therefore essential to double-edged role to understand psilocybin’s serotonergic effects in the context of IPF – as there are pro-fibrotic and anti-fibrotic aspects.

5-HT₂B receptor: a profibrotic risk? A wealth of evidence points to the 5-HT₂B-receptor as a key factor in tissue fibrosis. In IPF lungs, there is a increased expression 5-HT₂B receptors have been found, particularly on myofibroblasts in so-called fibroblastic foci (the active sites of fibrosis). Serotonin itself is often elevated in fibrotic lungs and binds to these receptors. The activation of 5-HT₂B on fibroblasts triggers an intracellular cascade (via G proteins, PI3K, Src kinase and PLC) which results in increased transcription of TGF-β₁ and PAI-1 – both are powerful drivers of fibrosis. TGF-β₁ stimulates the transformation of fibroblasts into myofibroblasts and the production of collagen, whilst PAI-1 contributes to matrix accumulation. It has been shown that inhibition of 5-HT₂B receptors a clear anti-fibrotic effect has. In fibrotic mouse models (bleomycin-induced pulmonary fibrosis), experimental 5-HT₂B antagonists led to reduced myofibroblast differentiation and reduced extracellular matrix deposition in the lung. Proliferation markers (such as p21^Waf1^) also decreased following 5-HT₂B blockade, suggesting a return to normal cell cycle control in fibroblasts. In vitro experiments confirm that serotonin administration causes human lung fibroblasts to hyperproliferate and disrupts their p21/Akt signalling pathway, whilst the addition of a 5-HT₂B antagonist largely repeals. In short, 5-HT₂B activation works pro-fibrotic and his block works anti-fibrotic.

What does this mean for psilocybin? Psilocin is a 5-HT₂B agonist. Although the affinity is slightly lower than that for 5-HT₂A, psilocin will certainly also bind to 5-HT₂B receptors at pharmacological doses. A single or sporadic dose of psilocybin might not be sufficient to induce a fibrotic effect in the lungs – fibrosis usually arises as a result of chronic stimulation. However, with repeated or prolonged use (e.g. microdosing several times a week), there is a real risk that 5-HT₂B-mediated fibrosis is triggered, in a similar way to what has been observed with other chronic serotonergic agents. The clearest example is methysergide: this 5-HT agonist caused severe fibrosis of the heart valves, retroperitoneum and even the pleura in a small percentage of users. LSD and psilocin are structurally similar to methysergide and fenfluramine (known for causing valvular heart disease), and in in vitro Assays have shown that LSD and psilocin are indeed capable of activating the 5-HT₂B receptor. In practical terms, this means that one must pay attention: Psilocybin could make fibrosis worse if the 5-HT₂B stimulation predominates. In IPF lungs, which already have an increased serotonergic drive, this is a cause for concern.

5-HT₂A receptor: a therapeutic target. On the other hand, the 5-HT₂A-receptor – the primary target of psilocybin’s psychedelic effect – has a different profile. 5-HT₂A is also elevated in IPF, but its functional role appears to be different. 5-HT₂A is found on immune cells and possibly also on epithelial cells and fibroblasts. Activation of 5-HT₂A outside the brain surprisingly, has anti-inflammatory and anti-fibrotic effects, as discussed. The spectacular reduction in pulmonary fibrosis in asthmatic mice induced by (R)-DOI was entirely mediated by 5-HT₂A activation. The mechanism underlying this is currently being investigated, but there are indications that 5-HT₂A agonists have a biased signalling may cause in immune cells. Instead of pro-inflammatory Gq pathways, psychedelics may, via 5-HT₂A, activate alternative pathways (e.g. β-arrestin or PI3K/Akt in certain cells) which, in fact, suppress inflammatory gene expression and activate protective genes. Furthermore, strong agonist binding often leads to internalisation and downregulation of receptors. Indeed, it has been observed that following a single high dose of psilocybin, the density of 5-HT₂A receptors in the brain decreases acutely (desensitisation). A similar downregulation in the lungs could mean that cells become less sensitive to the excess serotonin that promotes fibrosis. In other words: paradoxically, it may a pulsating agonist stimulus via 5-HT₂A result in a net anti-fibrotic effect by suppressing chronic serotonin signalling.

Other receptors: Psilocybin/psilocin also interacts with 5-HT₁A-receptors (for example, on neurons, but also on certain immune cells). 5-HT₁A agonism is known to have an anxiolytic effect and may reduce the release of stress hormones. Although not extensively studied in IPF, 5-HT₁A activation could potentially anti-fibrotic may be achieved by reducing indirect stress and inflammatory factors. 5-HT₂C receptors play a role primarily in the central sensation of satiety and mood, and their role in fibrosis is unclear – possibly minimal. The net effect The effects of psilocybin will therefore depend on a complex interplay between 5-HT₂B (undesirable pro-fibrotic) and 5-HT₂A (desirable anti-inflammatory/anti-fibrotic) receptors, as well as other receptors.

Summary of serotonergic effects: The serotonergic effect of psilocybin is a double cutting edge. On the one hand, there is a warning signal: prolonged stimulation of 5-HT₂B is clearly something that can cause fibrosis exacerbate, as seen with certain medicines. On the other hand, 5-HT₂A-mediated immunomodulation offers a chance: the use of psilocybin or specific analogues could lead to fibrosis to slow down by nipping inflammation and cell activation in the bud. It is essential that future research and any potential therapies take this balance sheet issue address – for example, by searching for substances that activate 5-HT₂A without overstimulating 5-HT₂B.

Outlook and conclusion

In view of the above, a mixed but intriguing picture emerges. Psilocybin and psilocin have biochemical effects that theoretically favourable For IPF, they activate rejuvenation pathways (SIRT1) that counteract fibrosis, reduce neuro- and systemic inflammation, and can modulate immune responses via 5-HT₂A receptors in such a way as to reduce fibrotic damage. Preclinical evidence supports various aspects of this puzzle – from prolonged survival of lung fibroblasts and reduced collagen deposition in mouse lungs to reduced oxidative damage and inflammatory reactivity.

At the same time, we must not overlook the risks and uncertainties. The probiotic serotonin axis (particularly 5-HT₂B) means that uncontrolled or chronic use of psychedelics could have adverse effects on the heart and lungs. Therefore, any potential therapeutic use of psilocybin in IPF would require careful dosage regimen require – for example occasional supervised administration, rather than frequent use. Another approach is to develop newly derived molecules (such as non-hallucinogenic 5-HT₂A-bias agonists). Such a compound could offer immunomodulatory benefits without the psychotropic effects and without strong 5-HT₂B activation. This is not science fiction: there are already derivatives under investigation that target inflammatory diseases whilst distinguishing between desired and undesired receptor effects.

Furthermore, a holistic approach is required. IPF is a complex disease, and it is unlikely that a single mechanism (such as SIRT1 activation alone or anti-inflammatory effects alone) completely halts fibrosis. However, psilocybin has a unique polypharmacological profile – it acts on several targets simultaneously (psychological, immunological, cellular). This could be beneficial in the case of a multifactorial condition such as IPF, provided that safety is ensured.

Current status and recommendations: For the time being, the therapeutic effect of psilocybin in IPF remains hypothetical. As far as we are aware, there are currently no clinical trials specifically for IPF. However, there is a growing body of literature on the systemic effects of psilocybin, such as on ageing and inflammation, which is being taken increasingly seriously. Research groups in the field of fibrosis are beginning to show an interest in serotonin pathways; for example, the 5-HT₂B receptor has already been proposed as a target for new anti-fibrotic drugs. Instead of an antagonist, one could also use a selective agonist (as psilocybin) could be used to inhibit fibrosis via receptor desensitisation and immunomodulation – an unconventional but fascinating idea. The first proof-of-concept in animals (reduced fibrosis in the lungs of mice following administration of a 5-HT₂A agonist) at least warrants further research.

Finally, there is the aspect of patient wellbeing. Regardless of any direct effect on fibrosis, controlled psilocybin therapy could quality of life can improve the quality of life of IPF patients by providing relief from the anxiety, depression and existential distress associated with this fatal disease. This in itself is a valuable therapeutic aim.

In conclusion: Psilocybin and psilocin lie at the interface between neuroscience and immunology and appear to have effects that extend to cellular ageing and fibrotic processes. There is both optimism (due to its anti-inflammatory, SIRT-activating and possible anti-fibrotic effects) as caution (due to the risks of serotonergic fibrosis) is required. Table 1 summarises the approaches and findings discussed. Ultimately, further research – ranging from cell culture to animal models and perhaps early-stage clinical trials – is necessary to determine whether psilocybin actually has a therapeutic weapon can be used against IPF, or is it mainly a scientific curiosity remains within this domain.

Table 1. Overview of relevant mechanisms of action of psilocybin/psilocin in relation to IPF

Conclusion: Current data – mainly preclinical – suggest that psilocybin/psilocin several points of reference which are relevant to IPF: it can slow down cellular ageing processes, modulate inflammatory responses and, via serotonergic pathways, exert both positive and negative effects on fibrosis. There is as yet no direct evidence that these effects translate into clinical benefit in IPF, but the concepts are theoretically underpinned and has been partially substantiated by experimental evidence (in cell and animal models). Whether psilocybin can actually be used as a treatment for IPF will depend on further research into its safety (prevention of 5-HT₂B-mediated side effects) and effectiveness (effects on fibrosis markers, lung function) is being investigated. Given the urgency of IPF as a disease and the unique mechanisms of action of psychedelics, this is a line of research that is likely to be explored further in the coming years – with the ultimate aim of gaining new insights and perhaps new treatment options to provide for IPF patients.